Hikma Pharmaceuticals PLC (HKMPF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hikma Pharmaceuticals PLC (HKMPF) with AI Score 45/100 (Weak). Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products across various therapeutic areas. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Hikma Pharmaceuticals PLC (HKMPF) Healthcare & Pipeline Overview
Hikma Pharmaceuticals PLC is a global pharmaceutical company specializing in generic, branded, and in-licensed products. Operating across Injectables, Generics, and Branded segments, Hikma serves diverse therapeutic areas and markets worldwide. The company distinguishes itself through a broad product portfolio and established presence in key regions, including the US, Europe, and MENA.
Investment Thesis
Hikma Pharmaceuticals PLC presents a compelling investment case based on its diversified product portfolio, global presence, and focus on both generic and branded pharmaceuticals. With a P/E ratio of 9.21 and a profit margin of 12.0%, Hikma demonstrates financial stability and profitability. The company's dividend yield of 5.02% offers an attractive income stream for investors. Growth catalysts include expansion into new therapeutic areas and geographic markets. Potential risks include regulatory challenges and competition from other generic drug manufacturers. The company's beta of 0.65 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $3.59 billion, reflecting Hikma's substantial size and market presence.
- P/E ratio of 9.21, indicating a potentially undervalued stock compared to industry peers.
- Profit margin of 12.0%, demonstrating efficient operations and profitability.
- Gross margin of 41.4%, showcasing Hikma's ability to maintain competitive pricing and cost control.
- Dividend yield of 5.02%, providing a significant income stream for investors.
Competitors & Peers
Strengths
- Diversified product portfolio.
- Global presence in key markets.
- Established manufacturing capabilities.
- Strong focus on both generic and branded products.
Weaknesses
- Dependence on generic drug sales, subject to price erosion.
- Exposure to regulatory risks and compliance requirements.
- Competition from larger pharmaceutical companies.
- Potential for product recalls and liability claims.
Catalysts
- Ongoing: Expansion into new therapeutic areas, such as biosimilars, to drive revenue growth.
- Ongoing: Geographic expansion in emerging markets to capitalize on increasing healthcare spending.
- Upcoming: Potential strategic acquisitions and partnerships to expand product portfolio and market reach.
- Ongoing: Development of specialty pharmaceuticals to target unmet medical needs and increase profit margins.
- Ongoing: Increased focus on injectable products to meet growing demand in hospitals and clinics.
Risks
- Potential: Increased competition from generic drug manufacturers leading to price erosion.
- Potential: Changes in healthcare regulations and reimbursement policies impacting profitability.
- Potential: Patent expirations and loss of exclusivity affecting revenue streams.
- Potential: Economic downturns and currency fluctuations impacting financial performance.
- Ongoing: Regulatory risks and compliance requirements in multiple jurisdictions.
Growth Opportunities
- Expansion into biosimilars: Hikma can leverage its manufacturing capabilities and regulatory expertise to develop and market biosimilar versions of complex biologic drugs. The global biosimilars market is projected to reach $35 billion by 2025, offering a significant growth opportunity for Hikma. This expansion requires strategic investments in research and development and navigating complex regulatory pathways.
- Geographic expansion in emerging markets: Hikma can further expand its presence in emerging markets, such as Asia and Latin America, where healthcare spending is increasing and access to medicines is improving. These markets offer significant growth potential for Hikma's generic and branded products. This expansion requires adapting to local regulatory requirements and building strong distribution networks.
- Strategic acquisitions and partnerships: Hikma can pursue strategic acquisitions and partnerships to expand its product portfolio, access new technologies, and enter new markets. This inorganic growth strategy can accelerate Hikma's expansion and enhance its competitive position. Identifying and integrating suitable acquisition targets is crucial for the success of this strategy.
- Development of specialty pharmaceuticals: Hikma can invest in the development of specialty pharmaceuticals targeting specific disease areas with unmet medical needs. This strategy can drive higher profit margins and differentiate Hikma from its competitors. This requires significant investment in research and development and navigating complex regulatory pathways.
- Increased focus on injectable products: Hikma's Injectables segment offers a strong growth opportunity due to the increasing demand for injectable medications in hospitals and clinics. Expanding the product portfolio and geographic reach of the Injectables segment can drive significant revenue growth. This requires investments in manufacturing capacity and regulatory approvals.
Opportunities
- Expansion into biosimilars market.
- Geographic expansion in emerging markets.
- Strategic acquisitions and partnerships.
- Development of specialty pharmaceuticals.
Threats
- Increased competition from generic drug manufacturers.
- Changes in healthcare regulations and reimbursement policies.
- Patent expirations and loss of exclusivity.
- Economic downturns and currency fluctuations.
Competitive Advantages
- Diversified product portfolio across multiple therapeutic areas.
- Global presence in key pharmaceutical markets.
- Established manufacturing capabilities and regulatory expertise.
- Strong relationships with healthcare providers and distributors.
About HKMPF
Founded in 1978 and headquartered in London, Hikma Pharmaceuticals PLC has evolved into a multinational pharmaceutical company. The company develops, manufactures, and markets a wide array of pharmaceutical products, including generics, branded medications, and in-licensed products. Hikma operates through three key segments: Injectables, Generics, and Branded. The Injectables segment focuses on supplying generic injectable products primarily to hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment provides branded generics and in-licensed products to both retail and hospital markets. Hikma's product portfolio covers various therapeutic areas, such as anti-infectives, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. The company has a significant presence in the United Kingdom, the United States, the Middle East, North Africa, Europe, and other international markets, reflecting its global reach and diverse customer base. Hikma's commitment to quality and innovation has enabled it to establish a strong position in the pharmaceutical industry.
What They Do
- Develops and manufactures generic pharmaceutical products.
- Markets and sells branded pharmaceutical products.
- Offers in-licensed pharmaceutical products.
- Provides injectable products for hospitals.
- Supplies oral and non-injectable generic products for retail markets.
- Operates in various therapeutic areas, including cardiovascular and oncology.
- Distributes products in the United Kingdom, the United States, and the Middle East.
Business Model
- Develops and manufactures pharmaceutical products.
- Sells products through three segments: Injectables, Generics, and Branded.
- Generates revenue from sales in various geographic regions.
- Focuses on both generic and branded pharmaceutical products.
Industry Context
Hikma Pharmaceuticals PLC operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and regulatory scrutiny. The global pharmaceutical market is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Hikma's focus on generic and branded products positions it to capitalize on the demand for affordable medications and specialized treatments. The company competes with other generic drug manufacturers and branded pharmaceutical companies, requiring continuous innovation and strategic partnerships to maintain its market share.
Key Customers
- Hospitals and clinics (Injectables segment).
- Retail pharmacies (Generics and Branded segments).
- Patients requiring prescription medications.
- Healthcare providers prescribing medications.
Financials
Chart & Info
Hikma Pharmaceuticals PLC (HKMPF) stock price: Price data unavailable
Latest News
No recent news available for HKMPF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HKMPF.
Price Targets
Wall Street price target analysis for HKMPF.
MoonshotScore
What does this score mean?
The MoonshotScore rates HKMPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Said Samih Taleb Darwazah
CEO
Said Samih Taleb Darwazah serves as the Chief Executive Officer of Hikma Pharmaceuticals PLC. His career spans several decades in the pharmaceutical industry, marked by leadership roles and a deep understanding of global healthcare markets. His expertise encompasses strategic planning, operational management, and business development. He is responsible for overseeing Hikma's global operations and driving its growth strategy. His leadership is pivotal in navigating the complexities of the pharmaceutical industry and ensuring Hikma's continued success.
Track Record: Under Said Samih Taleb Darwazah's leadership, Hikma Pharmaceuticals PLC has expanded its global presence and diversified its product portfolio. He has overseen strategic acquisitions and partnerships that have strengthened Hikma's competitive position. His focus on innovation and operational efficiency has contributed to Hikma's financial performance and shareholder value. He has successfully navigated regulatory challenges and maintained Hikma's commitment to quality and compliance.
HKMPF OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) securities. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure, may not meet minimum listing requirements, and are generally considered to be more speculative investments. These companies may be early-stage ventures, distressed entities, or foreign companies with limited US presence. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in HKMPF.
- Lower trading volume and liquidity can lead to price volatility.
- OTC Other stocks are subject to less regulatory oversight.
- Potential for fraud or manipulation is higher in the OTC market.
- Information asymmetry can disadvantage investors.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with OTC investing.
- Monitor trading volume and price movements.
- Consult with a financial advisor.
- Established history of operations since 1978.
- Global presence in multiple markets.
- Diversified product portfolio across therapeutic areas.
- Experienced management team led by Said Samih Taleb Darwazah.
- Presence in the Injectables, Generics, and Branded segments.
HKMPF Healthcare Stock FAQ
What does Hikma Pharmaceuticals PLC do?
Hikma Pharmaceuticals PLC is a global pharmaceutical company that develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. Hikma's products are used in various therapeutic areas, including anti-infectives, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. The company serves hospitals, retail pharmacies, and healthcare providers in the United Kingdom, the United States, the Middle East, North Africa, Europe, and other international markets. Hikma focuses on providing high-quality, affordable medicines to patients worldwide.
What do analysts say about HKMPF stock?
Analyst coverage for HKMPF may be limited due to its OTC listing. However, key valuation metrics such as the P/E ratio of 9.21 and dividend yield of 5.02% provide insights into the company's financial performance. Growth considerations include Hikma's expansion into new therapeutic areas and geographic markets. Investors should conduct their own due diligence and consider the risks associated with OTC investing. Analyst consensus may vary depending on the source and coverage.
What are the main risks for HKMPF?
The main risks for Hikma Pharmaceuticals PLC include increased competition from generic drug manufacturers, changes in healthcare regulations and reimbursement policies, patent expirations and loss of exclusivity, economic downturns and currency fluctuations, and regulatory risks and compliance requirements in multiple jurisdictions. As an OTC-listed company, HKMPF also faces risks related to limited financial disclosure, lower trading volume and liquidity, and potential for fraud or manipulation. Investors should carefully assess these risks before investing in HKMPF.
What are the key growth opportunities for HKMPF in healthcare?
Hikma Pharmaceuticals PLC has several key growth opportunities within the healthcare sector. These include expanding into the biosimilars market, which offers significant potential for revenue growth. Geographic expansion in emerging markets, where healthcare spending is increasing, also presents a substantial opportunity. Additionally, strategic acquisitions and partnerships can expand Hikma's product portfolio and market reach. The development of specialty pharmaceuticals targeting specific disease areas with unmet medical needs can drive higher profit margins. Finally, increasing the focus on injectable products can meet the growing demand in hospitals and clinics.
How does Hikma Pharmaceuticals PLC navigate regulatory approval processes?
Hikma Pharmaceuticals PLC navigates regulatory approval processes by maintaining a strong focus on quality and compliance. The company has established manufacturing capabilities and regulatory expertise to ensure its products meet the required standards. Hikma works closely with regulatory agencies, such as the FDA and EMA, to obtain approvals for its products in various markets. The company invests in research and development to support its regulatory filings and ensure compliance with evolving regulations. Hikma's commitment to quality and compliance is essential for maintaining its market access and reputation.
What are the key factors to evaluate for HKMPF?
Hikma Pharmaceuticals PLC (HKMPF) currently holds an AI score of 45/100, indicating low score. Key strength: Diversified product portfolio.. Primary risk to monitor: Potential: Increased competition from generic drug manufacturers leading to price erosion.. This is not financial advice.
How frequently does HKMPF data refresh on this page?
HKMPF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HKMPF's recent stock price performance?
Recent price movement in Hikma Pharmaceuticals PLC (HKMPF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis pending for HKMPF.